Belépés

NCT05748990Fut, nem toboroz

Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. szept. 25.

Rövid összefoglaló (regiszter, angolul)

Cognitive impairment (such as challenges in thinking and memory) is a core aspect of schizophrenia (SCZ), contributing to disability and poor functional outcomes. Additionally, almost half of the patients with SCZ are obese, the prevalence of type 2 diabetes is 3-6 times higher, and life expectancy is lower by 15-20 years compared to the general population. This is relevant as metabolic syndrome and diabetes are both associated with worse cognition among SCZ patients. Recent work studying the relationships between metabolic health and cognition has encouraged a new way of thinking about SCZ as both a metabolic and cognitive disorder. Brain insulin is involved in several processes relevant to SCZ, and abnormal brain insulin action may help explain both cognitive and metabolic abnormalities in patients with SCZ, but this has not been examined previously. Glucose uptake in several brain regions relevant to SCZ has been shown to be partially dependent on insulin. Therefore, in this study, the researchers will measure glucose uptake in the brain using an 18F-fluorodeoxyglucose ([18F]-FDG) positron emission tomography (PET) scan after an intranasal insulin stimulus, and will compare this measure between patients with SCZ and healthy controls.

Állapot (regiszter)
Fut, nem toboroz
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
20 (tervezett)
Első benyújtás
2023. febr. 18.
Kezdés
2023. ápr. 1.
Elsődleges befejezés
2026. dec. 31.
Fő szponzor
Centre for Addiction and Mental Health
Betegségek
Skizofrénia
NCT-szám
NCT05748990

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó
  • Tervezett résztvevők: 20
  • 2023. ápr. 1. és az elsődleges befejezés (2026. dec. 31.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Received maximum allowed radiation in the past 12 months (20 mSv)
  • current intake of any medication that may interfere with participation in the study or may confound the results of PET imaging (e.g. anti-diabetic medication).

Más betegség

  • liver or kidney disease
  • metallic cardiac valves
  • magnetic material such as surgical clips, implanted electronic infusion pumps or any other conditions that would preclude the MRI scan
  • history of head trauma resulting in loss of consciousness > 30 minutes that required medical attention;
  • unstable physical illness
  • significant neurological disorder including a seizure disorder;
  • Disorders of coagulation, blood or ongoing use of anticoagulant medication
    • Control group: Exclusionary criteria are as listed above for participants, in addition to:
  • First degree family member with primary psychotic disorder.

Laborértékek

  • prediabetes, diabetes, or evidence of impaired glucose tolerance on screening OGTT

Egyéb

  • moderate or severe substance use according to MINI (per PI discretion in the case of moderate alcohol or cannabis use)
  • acute suicidal risk
  • use of weight, lipid, antidiabetic or blood pressure reducing agents
  • pregnancy
  • nursing
  • pacemakers
  • clinically significant claustrophobia (determined from MRI screening form; significance evaluated as per QI's discretion).
  • size of head, neck, precluding to fit in the MRI or PET scanners
  • weight over 350lbs (limit for MRI scanner bed)
  • Completed more than 6 PET scans/ lifetime, that, together with the PET scanning procedures under this protocol will bring the total number of PET scans to more than the allowed/lifetime (8 PET scans per lifetime). These limits are set by the Centre for Addiction and Mental Health Brain Health Imaging Centre Guideline.
  • clinically relevant abnormality observed in medical history,

Kiket keres a vizsgálat

  • Experimental group (participants with a diagnosis of schizophrenia spectrum disorder):
  • 17-45 years
  • both sexes;
  • Patients with first-episode schizophrenia spectrum illness: Primary DSM-5 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder, psychotic disorder NOS, major depressive disorder with psychotic symptoms, bipolar I disorder, and bipolar II disorder, OR substance-induced psychosis, and antipsychotic treatment for schizophrenia, schizoaffective disorder, or other specified schizophrenia spectrum, other psychotic disorder, major depressive disorder with psychotic symptoms, bipolar I disorder, and bipolar II. (Diagnosis willbe confirmed via CAMH chart review).
  • BMI under or equal to 27
  • Control group (healthy controls):
  • 17-45 years of age
  • sex-,
  • hand dominance -and
  • body mass index (BMI)-matched
  • Absence of DSM-5 diagnosis other than a specific phobia according to MINI

Életkor a regiszterben: 17 év – 45 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Centre for Addiction and Mental Health
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát
TorontoKanadaIsmeretlen állapot

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.